This study investigates advanced solid tumors. It focuses on the use of a combination of antibodies targeting CTLA4, PD1, and PDL1.
The study evaluates the safety and effectiveness of these antibodies administered through different methods. It looks at how these methods might improve outcomes for patients with advanced solid tumors.
- Who can participate: Participants must be over 18 years old and have a confirmed diagnosis of cancer. They should meet certain health criteria and be willing to follow the study schedule.
- Study details: Participants will receive a combination of investigational medications through different delivery methods. A placebo may be used to compare effects.
How understandable was the trial content above?
Hard to understand
Easy to understand